EQT to acquire Europa Biosite, a distributor of life science products

EQT Healthcare Growth has agreed to acquire a majority stake of the shares in Europa Biosite – a distributor of high-quality research-use-only life science reagents, chemicals, and biological substances used in healthcare R&D – from Adelis Equity. Headquartered in Stockholm, Europa Biosite operates in 17 countries across Europe and North America and supports more than 60,000 researchers in academia and biopharma.

Europa Biosite offers access to over ten million individual scientific products essential to life sciences research, such as antibodies, biochemicals, diagnostic kits, and ethically sourced biospecimens, from a wide range of science-led suppliers. It has grown to become a partner for both suppliers and scientists, building on its highly localized footprint and strong technical sales capabilities.

Building on EQT’s three-decade track record in the healthcare sector, EQT Healthcare Growth seeks to scale healthcare companies by building their commercial muscle and expanding their reach. Europa Biosite will draw on this experience to expand its own-brand offering in biospecimens, continue its acquisition strategy to strengthen local market presence and expand to new geographies, and invest in new digital infrastructure.

EQT Healthcare Growth was advised by Mannheimer Swartling in the transaction.